Effects of presynaptic muscarinic cholinoreceptor blockade on neuromuscular transmission as assessed by the train-of-four and the tetanic fade response to rocuronium.

阅读:6
作者:Kim Yong Beom, Lee Sangseok, Lee Kyeong Chun, Kim Ha Jung, Ro Young Jin, Yang Hong-Seuk
This study investigated the effect of muscarinic M(1) and M(2) receptor antagonists on the rocuronium-induced train of four (TOF) fade and tetanic fade, respectively. Ex-vivo phrenic nerves and diaphragms were obtained from adult Sprague-Dawley rats and stabilized in Krebs buffer; the nerve-stimulated muscle TOF fade was observed at 20 s intervals. For the TOF study, phrenic nerves and diaphragms were incubated with pirenzepine (an M(1) blocker) at concentrations of 0 nmol L(-1) (control), 10 nmol L(-1) (PZP10), or 100 nmol L(-1) (PZP100). Rocuronium was then administered incrementally until the first twitch tension had depressed by >95% during TOF stimulation. The mean TOF ratios were compared when the first twitch tensions were depressed by 40%-50%. For the tetanic fade study, 50 Hz/5 s tetani was applied initially, 30 min after the administration of a loading dose of rocuronium and methoctramine (an M(2) receptor blocker, loaded at 0 μmol L(-1) [control], 1 μmol L(-1) [MET1], or 10 μmol L(-1) [MET10]). The EC(95) of rocuronium was significantly lower in the PZP10 group than in the control group. In the PZP10 group, the TOF ratios at 50% and first twitch tension depression were significantly lower than those in the control group (P=.02). During tetanic stimulation, the tetanic fade was significantly enhanced in the MET10 group compared to the other groups. This study shows that antagonists of muscarinic M(1) and M(2) receptors affect the rocuronium-induced neuromuscular block as demonstrated by the reduced EC(95) and TOF ratios (M(1) antagonist, pirenzepine) or the enhanced 50-Hz tetanic fade (M(2) antagonist, methoctramine).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。